Loading
Life sciences · Journal article
Virology Journal · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Influenza B virus (IBV) remains an important but comparatively underexamined contributor to seasonal influenza burden, particularly in children, adolescents, and older adults. Although IBV lacks the broad animal reservoir and pandemic potential of influenza A virus, its epidemiology, evolutionary dynamics, and contribution to variable vaccine effectiveness remain clinically and biologically important. Recent surveillance has further changed the field: no confirmed naturally circulating B/Yamagata-lineage viruses have been detected since March 2020, and current influenza B activity is overwhelmingly attributable to B/Victoria-lineage viruses. An important but still insufficiently developed dimension of IBV biology is immunogenetics. Variation in antigen presentation, innate sensing pathways, interferon responsiveness, and host dependency or restriction factors may contribute to heterogeneity in susceptibility, disease severity, cross-lineage immunity, and vaccine responsiveness. However, the strength of evidence varies across these domains, and much of the proposed framework still relies on inference from broader influenza literature rather than direct IBV-specific human data. In this review, we evaluate current evidence for immunogenetic determinants of IBV susceptibility and vaccine response, while distinguishing direct IBV findings from conclusions extrapolated from influenza A virus or general antiviral immunology. Available evidence identifies antigenic match, antigenic drift, age, exposure history, and baseline immunity as the best-supported non-genetic determinants of vaccine performance, whereas IBV-specific host-genetic predictors of susceptibility and vaccine response remain incompletely defined. We further highlight the major evidence gaps that limit predictive models of IBV immune control and vaccine performance, and outline priorities for future research, including integrated studies linking host genotype, immune phenotyping, and lineage-resolved virologic outcomes.